SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on a novel approach to chronic pain management and joint tissue preservation.
SN101 iPSC-derived therapy relieves chronic pain and preserves joints
- Post author:admin
- Post published:December 12, 2025
- Post category:uncategorized